Valuation dashboard for BridgeBio Pharma, Inc. (BBIO) with P/E N/A, P/B -5.23, EV/EBITDA -24.50 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Analysis Summary
BridgeBio Pharma, Inc. reported revenue of $502.1M in the most recent fiscal year, growing at a 5-year CAGR of 127.4%.
Trailing-twelve-month margins: gross margin 93.1%, operating margin -78.6%, net margin -100.6%.
At the current price of $66.14, BBIO has negative trailing earnings (P/E not meaningful) and an ROE of 31.67%. Market capitalisation stands at $13.0B, placing it among large-cap names.
Balance sheet quality for BBIO: current ratio of 2.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -5.23 |
| EV / EBITDA | -24.50 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-124.31 |
| vs Current Price | -287.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | $12.9B | 31.7% | ||
| ROIV | Roivant Sciences Ltd. | $25.8B | 6.09 | -6.1% | |
| MRNA | Moderna, Inc. | $75.4B | 11.13 | -39.2% | |
| ASND | Ascendis Pharma A/S | $14.2B | 16.85 | 9.13 | 190.4% |
| IONS | Ionis Pharmaceuticals, Inc. | $7.7B | 16.38 | -77.9% | |
| JAZZ | Jazz Pharmaceuticals plc | $14.9B | 15.50 | 3.10 | -8.2% |
| EXEL | Exelixis, Inc. | $14.9B | 17.75 | 7.94 | 42.5% |
| BMRN | BioMarin Pharmaceutical Inc. | $11.1B | 150.47 | 1.75 |
Price
| Price | $66.14 |
| Market Cap | $13.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 31.67% |
| Return on Invested Capital | -61.77% |
| Return on Assets | -57.20% |
| Gross Margin | 93.14% |
| Operating Margin | -78.56% |
| Net Margin | -100.64% |
Related companies: ASND · BMRN · EXEL · IONS · JAZZ · MRNA · RNA
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks